# Inhaled Treprostinil for PAH: Open-label Extension

> **NCT01557660** · PHASE3 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** inhaled treprostinil

## Key facts

- **NCT ID:** NCT01557660
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557660, "Inhaled Treprostinil for PAH: Open-label Extension". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01557660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*